- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05764551
The Application of Serum DNA Methylation for Patients With HCC
March 20, 2023 updated by: Chiayi Christian Hospital
he Application of DNA Methylation for Patients Who Had Hepatocellular Carcinoma With Normal Serum Alpha-fetoprotein
The goal of this single-arm prospective study is to evaluate the application of serum DNA methylation for HCC patients with normal alpha-fetoprotein. The main question it aims to answer is
. Is the dynamic change of serum DNA methylation correlated to recurrence or treatment response of HCC
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The enrolled individuals with HCC and normal serum alpha-fetoprotein level would receive serum DNA methylation test before their treatment (including all kinds of recommened HCC treatment).
Then regularly serum DNA methylation test would be done at 4th~8th weeks, 16th week, 32th week and 48th week.
If the enrolled patients did not have HCC recurrence during at 48th week.
The regular check of serum DNA methylation would be canceled.
The enrolled patients would be observed till 96th week.
If there is any recurrence during 48~96th week, one time of serum DNA methylation would be checked at the time of recurrence.
The observation and intervention would be completed at 96th week.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Po-Yueh Chen, M.D
- Phone Number: 5275 +886-5-2765041
- Email: hdilwy7@gmail.com
Study Contact Backup
- Name: Chia-Yi Chen, M.D
- Phone Number: 8636 +886-5-2765041
- Email: cych12497@gmail.com
Study Locations
-
-
-
Chiayi City, Taiwan, 600
- Recruiting
- Ditmanson Medical Foundation Chiayi Christian Hospital
-
Sub-Investigator:
- Chi-Yi Chen, MD
-
Sub-Investigator:
- Chu-Kuang Chou, MD
-
Principal Investigator:
- Po-Yueh Chen, MD
-
Contact:
- Po-Yueh Chen, MD
- Phone Number: 5275 +8862765041
- Email: hdilwy7@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 20 years old
- The diagnosis of hepatocellular carcinoma (HCC) according to AASLD 2018 clinical guidelines or histology report
- Individuals with HCC and normal serum alpha-fetorpotein level (<20 ng/ml)
- Individuals who could sign informed consent
Exclusion Criteria:
- The histology report revealed non-HCC, HCC mixed with cholangiocarcinoma or sarcomatoid HCC
- Individuals with HCC and other concurrent malignancies
- Individuals with chronic kidney disease who could not tolerate contrast-enhanced dynamic images
- Individuals ever receiving any organ transplantation
- Individuals with HIV infection
- Individuals who could not able to understand and sign informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DNA methylation
The enrolled individuals with HCC would receive serum DNA methylation test before their treatment (including all kinds of recommened HCC treatment).
Then regularly serum DNA methylation test would be done at 4th~8th weeks, 16th week, 32th week and 48th week.
If the enrolled patients did not have HCC recurrence during at 48th week.
The regular check of serum DNA methylation would be canceled.
The enrolled patients would be observed till 96th week.
If there is any recurrence during 48~96th week, one time of serum DNA methylation would be checked at the time of recurrence.
The observation and intervention would be completed at 96th week.
|
Serum DNA methylation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The correlation between serum DNA methylation and HCC recurrence or treatment response
Time Frame: 96 weeks
|
The correlation between serum DNA methylation and HCC recurrence or treatment response
|
96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Po-Yueh Chen, M.D, Ditmanson Medical Foundation Chiayi Christian Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 28, 2023
Primary Completion (Anticipated)
March 31, 2025
Study Completion (Anticipated)
March 31, 2026
Study Registration Dates
First Submitted
February 28, 2023
First Submitted That Met QC Criteria
February 28, 2023
First Posted (Actual)
March 10, 2023
Study Record Updates
Last Update Posted (Actual)
March 21, 2023
Last Update Submitted That Met QC Criteria
March 20, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB2022051
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on Serum DNA methylation
-
Shanghai Zhongshan HospitalNot yet recruitingStomach Neoplasms | Circulating Tumor DNA
-
Baylor Research InstituteActive, not recruitingEpithelial Ovarian CancerUnited States
-
Peking Union Medical College HospitalSecond Affiliated Hospital, School of Medicine, Zhejiang University; Zhejiang...RecruitingCervical Cancer | Cervical Intraepithelial Neoplasia | DNA Methylation | Cancer Screening | Detection AccuracyChina
-
Lei LiUnknownEndometrial Cancer | Liquid Biopsy | DNA Methylation | Diagnostic Accuracy | Cervical Cytology | Training Set | Validation SetChina
-
Lei LiThe Third Xiangya Hospital of Central South University; Women's Hospital School... and other collaboratorsRecruitingEndometrial Cancer | DNA Methylation | Cancer Screening | Cervical Cytology | Testing AccuracyChina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingColorectal NeoplasmsChina
-
Lei LiUnknownEpithelial Ovarian Cancer | Liquid Biopsy | DNA Methylation | Benign Ovarian Tumor | Training Set | Validation Set | Cell-free DNAChina
-
Lei LiBeijing Qiyuanjuhe Biotechnology Co., LtdRecruitingEndometrial Cancer | Cohort Study | Liquid Biopsy | DNA Methylation | Cancer Screening | Cervical CytologyChina
-
Jinling Hospital, ChinaUnknownCrohn Disease | Methylation | Illumina Human Methylation 850k BeadChipChina
-
Queen Mary University of LondonNational Cancer Institute (NCI)Recruiting